AQX-1125
( DrugBank: AQX-1125 / KEGG DRUG: - )
1 disease
| ID | Disease name (Link within this page) | Number of trials |
|---|---|---|
| 226 | Interstitial cystitis with Hunners ulcer | 10 |
226. Interstitial cystitis with Hunners ulcer
Clinical trials : 145 / Drugs : 156 - (DrugBank : 51) / Drug target genes : 64 - Drug target pathways : 146
Showing 1 to 10 of 10 trials
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2016-000906-12-NL (EUCTR) | 15/06/201720170615 | 19/07/201720170719 | A randomized study comparing Placebo and AQX-1125 in the treatment of subjects with Interstitial Cystitis/Bladder Pain Syndrome A randomized study comparing Placebo and AQX-1125in the treatment of subjects with Interstitial Cyst ... | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by a 40-Week Extension Period - The LEADERSHIP 301 Trial The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 A ... | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 19.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 MedDRA version: 19.1;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857 ;Therapeutic area: Not possible to specify Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 19.1;Level: LLT;Classification code 1007 ... | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United States;Spain;United Kingdom;Czech Republic;Hungary;Canada;Belgium;Poland;Romania;Denmark;Netherlands;Germany;Latvia United States;Spain;United Kingdom;Czech Republic;Hungary;Canada;Belgium;Poland;Romania;Denmark;Neth ... | ||
| 2 | EUCTR2016-000906-12-BE (EUCTR) | 24/04/201720170424 | 16/01/201720170116 | A randomized study comparing Placebo and AQX-1125 in the treatment of subjects with Interstitial Cystitis/Bladder Pain Syndrome A randomized study comparing Placebo and AQX-1125in the treatment of subjects with Interstitial Cyst ... | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period - The LEADERSHIP 301 Trial The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 A ... | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000017419 MedDRA version: 20.0;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000017419;Therapeutic area: Not possible to specify Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 20.0;Level: LLT;Classification code 1007 ... | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United States;Spain;United Kingdom;Czech Republic;Hungary;Canada;Belgium;Poland;Romania;Denmark;Germany;Latvia;Netherlands United States;Spain;United Kingdom;Czech Republic;Hungary;Canada;Belgium;Poland;Romania;Denmark;Germ ... | ||
| 3 | EUCTR2016-000906-12-ES (EUCTR) | 02/03/201720170302 | 16/01/201720170116 | A randomized study comparing Placebo and AQX-1125 in the treatment of subjects with Interstitial Cystitis/Bladder Pain Syndrome A randomized study comparing Placebo and AQX-1125in the treatment of subjects with Interstitial Cyst ... | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by a 40-Week Extension Period - The LEADERSHIP 301 Trial The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 A ... | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 19.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 MedDRA version: 19.1;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Not possible to specify Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 19.1;Level: LLT;Classification code 1007 ... | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United States;Spain;United Kingdom;Czech Republic;Hungary;Canada;Belgium;Poland;Romania;Denmark;Germany;Latvia;Netherlands United States;Spain;United Kingdom;Czech Republic;Hungary;Canada;Belgium;Poland;Romania;Denmark;Germ ... | ||
| 4 | EUCTR2016-000906-12-GB (EUCTR) | 23/11/201620161123 | 19/08/201620160819 | A randomized study comparing Placebo and AQX-1125 in the treatment of subjects with Interstitial Cystitis/Bladder Pain Syndrome A randomized study comparing Placebo and AQX-1125in the treatment of subjects with Interstitial Cyst ... | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period - The LEADERSHIP 301 Trial The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 A ... | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 19.1;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 MedDRA version: 20.0;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Not possible to specify Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 19.1;Level: LLT;Classification code 1007 ... | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United States;Hungary;Czech Republic;Canada;Poland;Belgium;Spain;Romania;Denmark;Netherlands;Latvia;United Kingdom United States;Hungary;Czech Republic;Canada;Poland;Belgium;Spain;Romania;Denmark;Netherlands;Latvia; ... | ||
| 5 | EUCTR2016-000906-12-LV (EUCTR) | 11/11/201620161111 | 01/08/201620160801 | A randomized study comparing Placebo and AQX-1125 in the treatment of subjects with Interstitial Cystitis/Bladder Pain Syndrome A randomized study comparing Placebo and AQX-1125in the treatment of subjects with Interstitial Cyst ... | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period - The LEADERSHIP 301 Trial The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 A ... | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 MedDRA version: 20.0;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Not possible to specify Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 20.0;Level: LLT;Classification code 1007 ... | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United States;Hungary;Czech Republic;Canada;Poland;Belgium;Spain;Romania;Denmark;Netherlands;Latvia;United Kingdom United States;Hungary;Czech Republic;Canada;Poland;Belgium;Spain;Romania;Denmark;Netherlands;Latvia; ... | ||
| 6 | EUCTR2016-000906-12-CZ (EUCTR) | 07/11/201620161107 | 27/07/201620160727 | A randomized study comparing Placebo and AQX-1125 in the treatment of subjects with Interstitial Cystitis/Bladder Pain Syndrome A randomized study comparing Placebo and AQX-1125in the treatment of subjects with Interstitial Cyst ... | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period - The LEADERSHIP 301 Trial The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 A ... | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 MedDRA version: 20.0;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Not possible to specify Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 20.0;Level: LLT;Classification code 1007 ... | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United States;Hungary;Czech Republic;Canada;Spain;Poland;Belgium;Romania;Denmark;Netherlands;Latvia;United Kingdom United States;Hungary;Czech Republic;Canada;Spain;Poland;Belgium;Romania;Denmark;Netherlands;Latvia; ... | ||
| 7 | EUCTR2016-000906-12-HU (EUCTR) | 23/09/201620160923 | 27/07/201620160727 | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by 14 or 40-Week Extension Periods - The LEADERSHIP 301 Trial The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 A ... | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by 14 or 40-Week Extension Periods - The LEADERSHIP 301 Trial The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 A ... | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 19.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 MedDRA version: 19.0;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Not possible to specify Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 19.0;Level: LLT;Classification code 1007 ... | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United States;Czech Republic;Hungary;Canada;Spain;Belgium;Poland;Romania;Denmark;Netherlands;Latvia;United Kingdom United States;Czech Republic;Hungary;Canada;Spain;Belgium;Poland;Romania;Denmark;Netherlands;Latvia; ... | ||
| 8 | EUCTR2016-000906-12-DK (EUCTR) | 07/09/201620160907 | 19/07/201620160719 | A randomized study comparing Placebo and AQX-1125 in the treatment of subjects with Interstitial Cystitis/Bladder Pain Syndrome A randomized study comparing Placebo and AQX-1125in the treatment of subjects with Interstitial Cyst ... | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the SHIP1 Pathway in Subjects with Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period - The LEADERSHIP 301 Trial The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3 A ... | Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 20.0;Level: LLT;Classification code 10071166;Term: Bladder pain syndrome;System Organ Class: 100000004857 MedDRA version: 20.0;Classification code 10008927;Term: Chronic interstitial cystitis;System Organ Class: 100000004857;Therapeutic area: Not possible to specify Interstitial Cystitis/Bladder Pain Syndrome MedDRA version: 20.0;Level: LLT;Classification code 1007 ... | Product Code: AQX-1125 INN or Proposed INN: AQX-1125 Other descriptive name: AQX-1125 | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Not Recruiting | Female: yes Male: yes | 600 | Phase 3 | United States;Hungary;Czech Republic;Canada;Poland;Belgium;Spain;Romania;Denmark;Netherlands;Latvia;United Kingdom United States;Hungary;Czech Republic;Canada;Poland;Belgium;Spain;Romania;Denmark;Netherlands;Latvia; ... | ||
| 9 | NCT02858453 (ClinicalTrials.gov) | July 201620160700 | 19/4/201620160419 | Efficacy and Safety of 2 Doses of AQX-1125 in Subjects With Interstitial Cystitis / Bladder Pain Syndrome Efficacy and Safety of 2 Doses of AQX-1125in Subjects With Interstitial Cystitis / Bladder Pain Synd ... | The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-Arm, Parallel-Group, Phase 3 Trial to Evaluate the Efficacy and Safety of 2 Doses of AQX-1125 Targeting the Src Homology 2-containing Inositol-5'-Phosphatase 1 (SHIP1) Pathway in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Followed by an Extension Period The LEADERSHIP 301 Trial: A 12-Week, Randomized, Multi-Center, Double-Blind, Placebo-Controlled, 3-A ... | Interstitial Cystitis;Bladder Pain Syndrome;Painful Bladder Syndrome;Chronic Interstitial Cystitis | Drug: AQX-1125 100 mg;Drug: AQX-1125 200 mg;Drug: Placebo | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Unknown status | 18 Years | 80 Years | All | 433 | Phase 3 | United States;Belgium;Canada;Czechia;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United Kingdom;Czech Republic United States;Belgium;Canada;Czechia;Denmark;Hungary;Latvia;Netherlands;Poland;Romania;Spain;United ... |
| 10 | NCT01882543 (ClinicalTrials.gov) | June 201320130600 | 18/6/201320130618 | Efficacy and Safety of AQX-1125 in IC/BPS | A Phase 2 Study to Evaluate the Efficacy and Safety of AQX-1125 in Subjects With Interstitial Cystitis/Bladder Pain Syndrome Mediated by the Src Homology-2-domain-containing Inositol 5' Phosphatase [SHIP1] Pathway A Phase 2 Study to Evaluate the Efficacy and Safety of AQX-1125in Subjects With Interstitial Cystiti ... | Interstitial Cystitis;Bladder Pain Syndrome | Drug: AQX-1125;Drug: Placebo | Aquinox Pharmaceuticals (Canada) Inc. | NULL | Completed | 18 Years | 75 Years | Female | 69 | Phase 2 | United States;Canada |